Starling Oncology annual operating margin
2020
2021
2022
2023
2024
2025
Starling Oncology's operating margin was −7.18% for fiscal 2025.
View full Starling Oncology company overview| Fiscal year | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −7.18% | +8.10 pp |
| 2024 | 2024-12-31 | −15.28% | +8.47 pp |
| 2023 | 2023-12-31 | −23.75% | +8.70 pp |
| 2022 | 2022-12-31 | −32.46% | −9.87 pp |
| 2021 | 2021-12-31 | −22.59% | −18.22 pp |
| 2020 | 2020-12-31 | −4.37% | — |
| Fiscal quarter | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −2.86% | +6.50 pp |
| Q1 2026 | 2026-03-31 | −4.42% | +5.08 pp |
| Q4 2025 | 2025-12-31 | −4.87% | +7.03 pp |
| Q3 2025 | 2025-09-30 | −5.90% | +7.97 pp |
| Q2 2025 | 2025-06-30 | −9.36% | +7.24 pp |
| Q1 2025 | 2025-03-31 | −9.49% | +9.49 pp |
| Q4 2024 | 2024-12-31 | −11.90% | +5.92 pp |
| Q3 2024 | 2024-09-30 | −13.87% | +3.11 pp |
| Q2 2024 | 2024-06-30 | −16.60% | +2.02 pp |
| Q1 2024 | 2024-03-31 | −18.98% | +24.15 pp |
| Q4 2023 | 2023-12-31 | −17.82% | +17.29 pp |
| Q3 2023 | 2023-09-30 | −16.97% | +13.95 pp |
| Q2 2023 | 2023-06-30 | −18.62% | +11.43 pp |
| Q1 2023 | 2023-03-31 | −43.14% | −9.65 pp |
| Q4 2022 | 2022-12-31 | −35.11% | +42.95 pp |
| Q3 2022 | 2022-09-30 | −30.93% | −26.80 pp |
| Q2 2022 | 2022-06-30 | −30.05% | −27.81 pp |
| Q1 2022 | 2022-03-31 | −33.49% | −29.88 pp |
| Q4 2021 | 2021-12-31 | −78.07% | — |
| Q3 2021 | 2021-09-30 | −4.13% | — |
| Q2 2021 | 2021-06-30 | −2.24% | — |
| Q1 2021 | 2021-03-31 | −3.61% | — |
Over the last five reported fiscal years, Starling Oncology's operating margin decreased from −4.37% to −7.18%, a change of −2.81 percentage points. The latest reported quarter, Q2 2026, shows −2.86%.
Operating margin measures the percentage of revenue left after operating costs and expenses. It shows how much operating profit a company generates from each dollar of revenue.
TickerStat calculates operating margin as SEC-reported operating income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Starling Oncology filings at SEC.gov ↗